These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 27270617)
1. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. Rahib L; Fleshman JM; Matrisian LM; Berlin JD JAMA Oncol; 2016 Sep; 2(9):1209-16. PubMed ID: 27270617 [TBL] [Abstract][Full Text] [Related]
2. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. Mosquera C; Maglic D; Zervos EE Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577 [TBL] [Abstract][Full Text] [Related]
3. [Possibilities of palliation in pancreatic cancer]. Di Costanzo F; Sdrobolini A; Gasperoni S Tumori; 1999; 85(1 Suppl 1):S47-53. PubMed ID: 10235081 [TBL] [Abstract][Full Text] [Related]
4. [The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review]. Azria D; Seblain-El-Guerche C; Girard N; Hennequin C; Huguet F Bull Cancer; 2008 Nov; 95(11):1116-30. PubMed ID: 19036684 [TBL] [Abstract][Full Text] [Related]
5. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. Philip PA; Chansky K; LeBlanc M; Rubinstein L; Seymour L; Ivy SP; Alberts SR; Catalano PJ; Crowley J Clin Cancer Res; 2014 Aug; 20(16):4176-85. PubMed ID: 24914040 [TBL] [Abstract][Full Text] [Related]
6. Cetuximab: still an option in the treatment of pancreatic cancer? Faloppi L; Andrikou K; Cascinu S Expert Opin Biol Ther; 2013 May; 13(5):791-801. PubMed ID: 23560505 [TBL] [Abstract][Full Text] [Related]
7. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020 [TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. Korn EL; Liu PY; Lee SJ; Chapman JA; Niedzwiecki D; Suman VJ; Moon J; Sondak VK; Atkins MB; Eisenhauer EA; Parulekar W; Markovic SN; Saxman S; Kirkwood JM J Clin Oncol; 2008 Feb; 26(4):527-34. PubMed ID: 18235113 [TBL] [Abstract][Full Text] [Related]
9. Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients. White MN; Dotan E; Catalano PJ; Cardin DB; Berlin JD J Geriatr Oncol; 2019 Jul; 10(4):540-546. PubMed ID: 30573201 [TBL] [Abstract][Full Text] [Related]
11. Second line treatment options for pancreatic cancer. Passero FC; Saif MW Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270 [TBL] [Abstract][Full Text] [Related]
12. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794 [TBL] [Abstract][Full Text] [Related]
13. Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. Dimou AT; Syrigos KN; Saif MW JOP; 2010 Jul; 11(4):324-7. PubMed ID: 20601803 [TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Kim EJ; Semrad TJ; Bold RJ Expert Opin Investig Drugs; 2015 Jun; 24(6):781-94. PubMed ID: 25809274 [TBL] [Abstract][Full Text] [Related]
16. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415. Adis International Ltd Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590 [TBL] [Abstract][Full Text] [Related]
17. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. Huguet F; André T; Hammel P; Artru P; Balosso J; Selle F; Deniaud-Alexandre E; Ruszniewski P; Touboul E; Labianca R; de Gramont A; Louvet C J Clin Oncol; 2007 Jan; 25(3):326-31. PubMed ID: 17235048 [TBL] [Abstract][Full Text] [Related]
18. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Hochster HS; Haller DG; de Gramont A; Berlin JD; Philip PA; Moore MJ; Ajani JA Cancer; 2006 Aug; 107(4):676-85. PubMed ID: 16847885 [TBL] [Abstract][Full Text] [Related]
19. Phase-II trials in osteosarcoma recurrences: A systematic review of past experience. Omer N; Le Deley MC; Piperno-Neumann S; Marec-Berard P; Italiano A; Corradini N; Bellera C; Brugières L; Gaspar N Eur J Cancer; 2017 Apr; 75():98-108. PubMed ID: 28219023 [TBL] [Abstract][Full Text] [Related]